This report was first published by Endpoints News. To see the original version, click here
Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO.
The Flagship Pioneering-backed startup has become a richly-funded leader of AI bio since its founding in 2018. The company has brought in $934 million, signed pharma partnerships with Amgen and Novartis, and is the first AI-focused biotech to enter Phase 3 with its lead drug program.
您已阅读9%（483字），剩余91%（4768字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。